Search Results - "DOWLATI, A"

Clinical correlation of extensive-stage small-cell lung cancer genomics by Dowlati, A., Lipka, M.B., McColl, K., Dabir, S., Behtaj, M., Kresak, A., Miron, A., Yang, M., Sharma, N., Fu, P., Wildey, G.

“…Genomic studies in small-cell lung cancer (SCLC) lag far behind those carried out in nonsmall-cell lung cancer (NSCLC). To date, most SCLC studies have…”
Get full text

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study by Hong, D.S., Bauer, T.M., Lee, J.J., Dowlati, A., Brose, M.S., Farago, A.F., Taylor, M., Shaw, A.T., Montez, S., Meric-Bernstam, F., Smith, S., Tuch, B.B., Ebata, K., Cruickshank, S., Cox, M.C., Burris, H.A., Doebele, R.C.

“…NTRK1, NTRK2 and NTRK3 gene fusions (NTRK gene fusions) occur in a range of adult cancers. Larotrectinib is a potent and highly selective ATP-competitive…”
Get full text

Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263 by Greenberg, E F, McColl, K S, Zhong, F, Wildey, G, Dowlati, A, Distelhorst, C W

“…Small cell lung cancer (SCLC) has an annual mortality approaching that of breast and prostate cancer. Although sensitive to initial chemotherapy, SCLC rapidly…”
Get full text

Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer by Tang, Z, Du, R, Jiang, S, Wu, C, Barkauskas, D S, Richey, J, Molter, J, Lam, M, Flask, C, Gerson, S, Dowlati, A, Liu, L, Lee, Z, Halmos, B, Wang, Y, Kern, J A, Ma, P C

“…Despite clinical approval of erlotinib, most advanced lung cancer patients are primary non-responders. Initial responders invariably develop secondary…”
Get full text

Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States by Jain, P., Gutierrez Bugarin, J., Guha, A., Jain, C., Patil, N., Shen, T., Stanevich, I., Nikore, V., Margolin, K., Ernstoff, M., Velcheti, V., Barnholtz-Sloan, J., Dowlati, A.

“…Immune checkpoint inhibitors (ICIs) can cause life-threatening cardiovascular adverse events (CVAEs) that may not be attributed to therapy. The outcomes of…”
Get full text

Activity of larotrectinib in patients with TRK fusion GI malignancies by Nathenson, M., Demetri, G., Lassen, U., Hong, D., Boni, V., Deeken, J., Dowlati, A., Cox, M., Ku, N., Cruickshank, S., Qamoos, H., Drilon, A.

Get full text

Comparison of Overall and Cause-Specific Survivals of Stage III Non-Small Cell Lung Cancer (NSCLC) Treated With Carboplatin- or Cisplatin-Based Concurrent Chemoradiation Therapy Using SEER-Medicare Data (1992-2007) by Kim, E, Biswas, T, Dowlati, A, Sharma, N, Machtay, M

Get full text

Comparison of Overall and Cause-Specific Survivals of Stage 3 Non-Small Cell Lung Cancer (NSCLC) Treated With Carboplatin or Cisplatin-Based Concurrent Chemoradiation Therapy Using SEER-Medicare Data (1992-2007) by Kim, E, Biswas, T, Dowlati, A, Sharma, N, Machtay, M

Get full text

Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer by Rudin, C.M., Cervantes, A., Dowlati, A., Besse, B., Ma, B., Costa, D.B., Schmid, P., Heist, R., Villaflor, V.M., Spahn, J., Li, S., Cha, E., Riely, G.J., Gettinger, S.

“…Acquired resistance limits long-term epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) efficacy in patients with EGFR mutation-positive…”
Get full text

A Pharmacokinetic and Safety Study of Trebananib, an Fc‐Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction by Wu, B, Lewis, LD, Harvey, RD, Rasmussen, E, Gamelin, E, Sun, Y‐N, Friberg, G, Koyner, JL, Dowlati, A, Maitland, ML

“…Clearance of trebananib (AMG 386), a 64‐kD antiangiogenic peptibody, has been associated with estimated glomerular filtration rate (eGFR). We prospectively…”
Get full text

Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions by Hong, D.S, Dowlati, A, Burris, H.A, Lee, J.J, Brose, M.S, Farago, A.F, Bauer, T.M, Taylor, M, Shaw, A.T, Smith, S, Nanda, N, Cruikshank, S, Cox, M.C, Doebele, R.C

Get full text

441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC by Ma, B.B.Y., Rudin, C.M., Cervantes, A., Dowlati, A., Costa, D., Schmid, P., Heist, R., Villaflor, V.M., Sarkar, I., Huseni, M.A., Foster, P., O'Hear, C., Gettinger, S., Besse, B.

Get full text

Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies by Tan, A R, Dowlati, A, Stein, M N, Jones, S F, Infante, J R, Bendell, J, Kane, M P, Levinson, K T, Suttle, A B, Burris III, H A

“…Background: We assessed the maximum tolerated regimen (MTR) and dose-limiting toxicities of pazopanib and lapatinib in combination with weekly paclitaxel, and…”
Get full text

Corrigendum to ‘Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States’: [ESMO Open Volume 6, Issue 5, October 2021, 100252] by Jain, P., Gutierrez Bugarin, J., Guha, A., Jain, C., Patil, N., Shen, T., Stanevich, I., Nikore, V., Margolin, K., Ernstoff, M., Velcheti, V., Barnholtz-Sloan, J., Dowlati, A.

Get full text

Brentuximab Vedotin in Patients With CD30+ Mesothelioma by Jalal, S.I, Einhorn, L, Shapiro, G.I, Hilton, J, Wheler, J, Dowlati, A, Josephson, N, Sharman, J, Burke, J.M

Get full text

Combining Pemetrexed With Methoxyamine to Enhance the Radiosensitization of Non-Small Cell Lung Cancer (NSCLC): Preclinical Studies In Vivo by Biswas, T, Patel, R, Weeks, L, Sharma, N, Dowlati, A, Oleinick, N.L, Gerson, S.L, Machtay, M.X

Get full text

Enhanced Radiosensitization of Lung Adenocarcinoma Cells by Pemetrexed When Combined With Methoxyamine to Inhibit Base Excision Repair by Biswas, T, Patel, R, Weeks, L, Dowlati, A, Sharma, N, Oleinick, N, Gerson, S, Machtay, M

Get full text

Simpson’s paradox – aggregating and partitioning populations in health disparities of lung cancer patients by Fu, P, Panneerselvam, A, Clifford, B, Dowlati, A, Ma, PC, Zeng, G, Halmos, B, Leidner, RS

“…It is well known that non-small cell lung cancer (NSCLC) is a heterogeneous group of diseases. Previous studies have demonstrated genetic variation among…”
Get full text

Improved 4-year Overall and Local Failure-free Survival in Stage IIIA Non-small Cell Lung Cancer After High-dose, 3D Conformal RT (3DCRT) ± Chemotherapy (CT) - A Single Institution Experience by Greskovich, J.F, Machtay, M, Dill, S, Kan, C, Fu, P, Jiang, Y, Dowlati, A, Ellis, R

Get full text

A PHASE 1 STUDY OF BET INHIBITION USING RG6146 IN RELAPSED/REFRACTORY (R/R) MYC‐EXPRESSING DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) by Caimi, P.F., Eder, J.P., Jacobsen, E.D., Jacobson, C.A., LaCasce, A.S., Shipp, M.A., Chapuy, B., Labriola‐Tomphins, E., Boisserie, F., Passe, S., Chesné, E., Pierceall, W., Zhi, J., DeMario, M., Vaishampayan, U., Dowlati, A., Shapiro, G.I., Fisher, D.C., Armand, P.

Get full text